Alterations in genes of the DNA damage response (DDR) represent a significant subset of actionable genetic alterations in pancreatic cancer, particularly due to their association with homologous recombination repair deficiency (HRD). PARP inhibitors (PARPi), such as olaparib, have emerged as a promising therapeutic strategy for BRCA2-mutant PDAC by exploiting synthetic lethality. However, several challenges limit their widespread application. Tumour heterogeneity, the development of resistance mechanisms and the lack of reliable response biomarkers diminishes the efficacy of PARP inhibitors.This study will establish novel therapeutic strategies for increasing the efficacy of DDR agents in PDAC, refine biomarkers to select for patients most likely to respond (or not) to PARPi, and will offer innovative interventions to overcome inherent and acquired PARPi resistance. Here we will build rationale from pre-clinical experiments that have potential to translate to early-phase clinical trials bringing together design and testing of synthetic combination strategies and associated companion biomarkers.
Targeted DDR agents such as PARP inhibitors have shown promise in BRCA2 mutated pancreatic cancers. However patients with DDR alterations (non-BRCA2) may also benefit from PARPi or other DDR inhibitor drugs.
Breast cancer remains the leading cause of cancer deaths among women, even though diagnosis and treatment have improved greatly. Current treatments can only target specific genetic changes (mutations) in about 40% of patients, which means many women don’t benefit from existing options. This shows the need to find new drug targets.
Traditionally, researchers have focused on mutations in the parts of our DNA that make proteins. But growing evidence shows that changes in the “non‑coding” regions of DNA—areas that don’t directly make proteins—can also drive cancer. These non‑coding mutations may serve as important markers for developing new treatments or choosing the right therapy.
Large studies that look at the entire genome have already found promising non‑coding mutations in breast cancer patients. The challenge now is figuring out which of these changes actually drive cancer and which are harmless. Studying and testing these mutations is essential to deepen our understanding of breast cancer and to create more precise, personalised treatments that improve patient care.
Scientists need to functionally determine the role of frequently occurring oncogenic non-coding mutations to identify those that drive cancer and could act as predictors of therapy response.